PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer
February 23 2017 - 1:00AM
Business Wire
PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a
cross-disciplinary biopharmaceutical company, today announced the
appointment of Atul Pande, M.D., as the Company’s Chief Medical
Officer. In this new role, Dr. Pande will oversee all clinical
operations across PureTech Health’s pipeline and work closely with
the team to de-risk and advance opportunities that hold the most
potential for patients.
Dr. Pande commented: “I am proud and delighted to join this
stellar team and hope to be instrumental in enabling the launch of
some of the truly innovative medicines in the PureTech Health
pipeline. Having been involved in clinical research and development
for more than twenty years, I believe that the PureTech Health
approach – which starts with ground-breaking science and signals of
human efficacy and stresses safety – has important advantages.”
“We are excited to work more closely with Atul and to have
access to his drug development expertise across PureTech Health’s
pipeline,” said Daphne Zohar, Chief Executive Officer of PureTech
Health. “Atul is a seasoned drug development veteran who will help
to shepherd our advancing pipeline through mid- and late-stage
clinical trials while ensuring that synergies are leveraged across
our platforms.”
Dr. Pande has more than two decades of experience in drug
development. He is the former Senior Vice President, Head of
Neuroscience, and Senior Advisor, Pharmaceutical R&D at
GlaxoSmithKline. Dr. Pande has been active in the development of
multiple investigational and now marketed drugs while holding
various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert,
and Lilly Research Laboratories. His experience includes drug
development, registration, launch and lifecycle management in the
areas of anxiety, depression, epilepsy, neuropathic pain,
schizophrenia, traumatic brain injury, and Alzheimer's and
Parkinson's diseases. Dr. Pande is a psychiatrist and fellow of
several scientific societies, including the American Psychiatric
Association. He currently serves on the Board of Directors of
PureTech’s Karuna Pharmaceuticals. He also sits on the Board of
Axovant Sciences (NYSE:AXON), and Autifony Therapeutics and on the
Scientific Advisory Board of Cennerv Pharma. Dr. Pande began his
career as a faculty member at the University of Michigan Medical
School where his research focused on mood disorders. He has
published over 50 peer-reviewed scientific papers and over 100
abstracts, book chapters, and book reviews.
About PureTech HealthPureTech Health (PureTech
Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical
company creating 21st century medicines that modulate the adaptive
human systems. Our therapies target the immune, nervous, and
gastro-intestinal systems by addressing the underlying
pathophysiology of disease from a systems perspective rather than
through a single receptor or pathway. We have multiple human
proof-of-concept studies and pivotal or registration studies
expected to read out in the next two years. PureTech Health’s rich
and growing research and development pipeline has been developed in
collaboration with some of the world’s leading scientific experts
who, along with PureTech's experienced team and board, analyze more
than 650 scientific discoveries per year to identify and advance
only the opportunities we believe hold the most promise for
patients. This team and process place PureTech Health on the
cutting edge of ground-breaking science and technological
innovation and leads the Company between and beyond existing
disciplines. For more information, visit www.puretechhealth.com or
connect with us on Twitter.
Forward Looking StatementThis press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170222006558/en/
PureTech HealthMedia:Allison Mead, +1 617 651
3156amead@puretechhealth.comorInvestors:Graham Morrell, +1 617 986
1659gm@puretechhealth.com
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024